Clinical case 1 | |
Mother’s age, years | 31 |
Gestational age, weeks | 14 |
Induction chemotherapy | -Induction: daunorubicin 50 mg/m2 (days 1, 3, 5) and cytosine arabinoside 3 g/m2 (days 1–5) -Reinduction: fludarabine 30 mg/m2 (days 1–4), cytosine arabinoside 2 g/m2 (days 1–4) and idarubicin 12 mg/m2 (days 1–4) |
Consolidation treatment | -Cytosine arabinoside 3 g/m2 twice a day (days 1–3-5) -Myeloablative sibling HSCT (conditioning regimen: busulfan 0,8 mg/kg three times a day days −9 -8 -7 -6 and cyclophosphamide 60 mg/kg days −3 -2) |
Maternal outcome | CR |
Fetal outcome | Surgical abortion at AML diagnosis |
Delivery | - |
Clinical case 2 | |
Mother’s age (years) | 36 |
Gestational age (weeks) | 32 |
Induction chemotherapy | Daunorubicin 50 mg/m2 (days 1, 3, 5) and cytosine arabinoside 3 g/m2 (days 1–5) |
Consolidation treatment | -Cytosine arabinoside 3 g/m2 twice a day (days 1–4), daunorubicin 50 mg/m2 (days 5–6) -Cytosine arabinoside 300 mg/m2 (days 1–5), daunorubicin 50 mg/m2 (days 1–2) -Cytosine arabinoside 300 mg/m2 (days 1–5), etoposide 150 mg/m2 (days 1–3) -Cytosine arabinoside 1 g/m2 twice a day (days 1, 3, 5) -Autologous HSCT (conditioning regimen: cytosine arabinoside 3 g/m2 twice a day, cyclophosphamide 60 mg/kg twice a day for two days, 1000 cGy of total body irradiation) |
Maternal outcome Fetal outcome Delivery | CR Live birth, normal child Cesarean at AML diagnosis |
Clinical case 3 | |
Mother’s age (years) | 32 |
Gestational age (weeks) | 26 |
Induction chemotherapy | Cytosine arabinoside 2Â g/m2 twice a day (days 1, 2, 8, 9) and idarubicin 18Â mg/m2 (days 2, 3, 10) 6Â weeks after delivery when MDS progressed to AML |
Consolidation treatment | -Cytosine arabinoside 100 mg/m2 (days 1–7), idarubicin 10 mg/m2 (days 1–3) -Myeloablative sibling HSCT (conditioning regimen: busulfan 0.8 mg/kg three times a day, days −9 -8 -7 -6, cyclophosphamide 60 mg/kg, days −3 -2) |
Maternal outcome Fetal outcome Delivery | CR Live birth, normal child Cesarean at 32Â +Â 2Â weeks after administration of betamethasone |
Clinical case 4 | |
Mother’s age (years) | 34 |
Gestational age (weeks) | 31 |
Induction chemotherapy | Cytosine arabinoside 3 g/m2 (days 1–5) and daunorubicin 50 mg/m2 (days 2, 4, 5) |
Consolidation treatment | -Cytosine arabinoside 3 g/m2 twice a day (days 1–4), daunorubicin 50 mg/m2 (days 5–6) −2 cycles of cytosine arabinoside 3 g/m2 twice a day (days 1–3-5) |
Maternal outcome Fetal outcome Delivery | CR Intrauterine fetal death Cesarean at AML diagnosis |
Clinical case 5 | |
Mother’s age (years) | 39 |
Gestational age (weeks) | 24Â +Â 5 |
Induction chemotherapy | Cytosine arabinoside 100 mg/m2 (days 1–7) and daunorubicin 40 mg/m2 (days 1–3) |
Consolidation treatment | 4 cycles of cytosine arabinoside 3 g/m2 twice a day (days 1–3-5) |
Maternal outcome | CR; death for septic shock during the fourth and last consolidation cycle with high dose cytosine arabinoside |
Fetal outcome Delivery | Live birth, normal child Cesarean at 30Â weeks after administration of betamethasone |